Do Patients with Marfan Syndrome Have Increased Cancer Risk?
Based on the most recent and highest-quality evidence, patients with Marfan syndrome do have an increased cancer risk, particularly in childhood and for specific cancer types, though the overall adult cancer risk remains uncertain and requires heightened clinical awareness rather than routine surveillance protocols.
Evidence Summary
Childhood Cancer Risk
The strongest and most recent evidence from a Swedish population-based cohort study demonstrates a more than two-fold increased risk of cancer in children with Marfan syndrome (HR 2.44,95% CI 1.25-4.80) 1. This represents the highest quality data available, using nationwide registry data from 1,544 individuals with Marfan syndrome matched to 77,200 comparisons.
Adult Cancer Risk
The evidence for adult cancer risk is more nuanced:
The 2026 Swedish study found no increased overall adult cancer risk (HR 1.00,95% CI 0.78-1.27), but did identify a nearly three-fold increased risk of endocrine tumors specifically (HR 2.86,95% CI 1.40-5.85) 1
Contrasting evidence from Taiwan (2017) showed patients with Marfan syndrome had significantly higher overall malignancy risk (adjusted OR 3.991), with particular increases in head/neck and urinary tract cancers 2
Specific Cancer Types Reported
Case reports and small series have documented:
- Neuroblastoma (two recent pediatric cases with early onset and unfavorable features) 3
- Thyroid carcinoma with unusual villous papillary patterns 4
- Various hematological malignancies 5
Clinical Implications
What This Means for Practice
For children with Marfan syndrome:
- Maintain heightened clinical suspicion for malignancy
- Promptly evaluate any concerning symptoms (unexplained masses, persistent pain, constitutional symptoms)
- The absolute risk remains relatively low, so routine cancer screening protocols are not currently recommended by available guidelines
For adults with Marfan syndrome:
- Be particularly vigilant for endocrine tumors (thyroid nodules, adrenal masses)
- Investigate head/neck and urinary tract symptoms thoroughly
- No specific cancer surveillance protocols are established in current cardiovascular-focused guidelines 6, 7, 8
Important Caveats
The evidence is conflicting between the Swedish and Taiwanese studies regarding overall adult cancer risk, likely reflecting different populations, healthcare systems, and study methodologies
Current Marfan syndrome guidelines focus exclusively on cardiovascular complications and do not address cancer surveillance 6, 7, 8
The biological mechanism may involve dysregulated TGF-β signaling, which participates in both Marfan pathophysiology and malignant transformation 2, 4
Early cancer onset is characteristic - reported cases show younger age at diagnosis compared to general population 3
Practical Approach
Maintain clinical awareness without implementing routine screening:
- Document any family history of cancer in addition to standard Marfan-related family history
- Investigate concerning symptoms promptly rather than attributing them to Marfan-related musculoskeletal issues
- Consider endocrine evaluation (thyroid examination, appropriate imaging) if clinically indicated
- For pediatric patients, ensure primary care providers are aware of the modestly elevated childhood cancer risk
Do not:
- Order routine cancer screening beyond age-appropriate population recommendations
- Delay cardiovascular surveillance or management (which remains the primary mortality risk) 7
- Create undue anxiety, as absolute cancer risk remains relatively low
The cardiovascular complications of Marfan syndrome (aortic dissection, rupture) remain the predominant cause of morbidity and mortality 7, and management should continue to prioritize these life-threatening complications while maintaining appropriate awareness of potential malignancy risk.